Rocket – Talk Bio

Rocket Pharmaceuticals Cuts 30% of Staff, Refocuses on Heart Gene Therapies

1 day ago talkbio0Tagged 30%, Anemia, BAG3-associated, cardiovascular gene therapy, Deficiency of pyruvate kinase, Dependovirus, Financial cost, Glycogen Storage Disease Type IIb, Kresladi, layoffs, PKP2-associated cardiomyopathy, restructuring, Rocket

Rocket Pharmaceuticals; layoffs; restructuring; 30% workforce reduction; cardiovascular gene therapy; adeno-associated virus (AAV); Danon disease; PKP2-associated cardiomyopathy; BAG3-associated dilated cardiomyopathy; operating cost reduction; Fanconi Anemia; Pyruvate Kinase Deficiency; KRESLADI

Patient Death in Rocket Pharmaceuticals Gene Therapy Trial Prompts FDA Clinical Hold

2 months ago talkbio0Tagged acute systemic infection, Adverse event, Capillary Leak Syndrome, gene therapy, Glycogen Storage Disease Type IIb, Patient Death, Rocket, RP-A501, Study on Hold, United States Food and Drug Administration

Rocket Pharmaceuticals; gene therapy; Danon disease; clinical hold; FDA; patient death; capillary leak syndrome; acute systemic infection; RP-A501; adverse event

Rocket Pharmaceuticals Expands Leadership with J&J and AstraZeneca Alumni to Strengthen Gene Therapy Commercialization

4 months ago talkbio0Tagged AstraZeneca, Biotechnology, Chaudhuri, commercial, gene therapy, Kresladi, launch, Market, Mozafancogene Autotemcel, Rocket, Sarbani

Rocket Pharmaceuticals, gene therapy, commercial leadership, Sarbani Chaudhuri, Johnson & Johnson, AstraZeneca, commercial launch, gene therapy market, rare diseases, biotechnology, Kresladi, RP-L102.

FDA Rejects Rocket Pharmaceuticals’ Gene Therapy for Ultra-Rare Immune Disease Over Manufacturing Concerns

1 year ago talkbio0Tagged concerns, deficiency-I, gene therapy, LAD-I, leukocyte cell-cell adhesion, Manufacture, Rocket, United States Food and Drug Administration

FDA, Rocket Pharmaceuticals, Gene Therapy, Leukocyte Adhesion Deficiency-I (LAD-I), Manufacturing Concerns

FDA Rejects Rocket Pharmaceuticals’ Gene Therapy for Ultra-Rare Immune Disease, Requests Additional Manufacturing Information

1 year ago talkbio0Tagged Complete, control act - information, deficiency-I, gene therapy, LAD-I, leukocyte cell-cell adhesion, Manufacture, Response process, Rocket, United States Food and Drug Administration

FDA, Rocket Pharmaceuticals, Gene Therapy, Leukocyte Adhesion Deficiency-I (LAD-I), Manufacturing Information, Complete Response Letter

Revolutionary Gene Therapy Advancements: Early Trial Results from Leading Biotech Companies

1 year ago talkbio0Tagged ASGCT24, Clinical Trials, Creyon, Freeline, gene therapy, Hemophilia A, Hereditary Diseases, Liver diseases, Parkinson 's disease, Rocket

ASGCT24, gene therapy, early trial results, Freeline, Rocket, Creyon, biotech companies, genetic diseases, hemophilia, liver diseases, Parkinson’s disease.